NEUROCRINE BIOSCIENCES INC (NBIX)
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business